Haisco Pharmaceutical Group (SHE:002653) subsidiary Haisiseno Pharmaceutical obtained acceptance from China's medical products administrator for an investigational new drug application covering a new indication of HSK36357 capsules for treating muscular dystrophy.
The drug is already approved for clinical testing in peripheral neuropathic pain, according to a Friday filing with the Shenzhen bourse.
Shares of the pharmaceutical company were down 2% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments